Bill joined Vigilant Biosciences in the summer of 2018 as CEO to lead the Company’s transition from a development organization to a successful commercial enterprise. Bill brings over 20 years of experience in management roles. Previously, he served as Chief Commercial Officer of Vital Connect, a leader in wearable biosensor technology for wireless hospital and remote patient monitoring. He earlier served as Global Vice President of Sales and Marketing at myoscience where he built and led all commercial operations. Bill also served as Vice President of Global Sales at Solta Medical. From 1998 to 2006, Bill served as Vice President of Sales and Field Operations and held various sales management positions with Benco Dental, a $400M company specializing in dental office equipment sales, office design and supply management. His expertise includes team leadership, sales management and international business management.
Bill earned a Master of Science in Management from Georgia Institute of Technology and a Bachelor of Science in Mathematics from Rollins College.
Robert joined Vigilant Biosciences in 2015 as the Chief Financial Officer and VP of Administration. Rob is a former Big–Four CPA with 20+ years of public company and venture–backed private portfolio company experience having worked with companies in e–commerce, health and fitness, technology and retail/wholesale industries. Prior to Vigilant Biosciences, Rob served as CFO of Bridgevine, Inc., a privately held and venture–backed e–commerce solution. Prior to that, he was the CFO of eDiets, Inc. (formerly NASDAQ- DIET), a leading provider of online weight loss solutions. Rob began his career as an auditor with Arthur Andersen, LLP in Boston. Progressing to audit manager, he serviced multinational SEC and non–public clients in the high technology, manufacturing, retail/wholesale distribution, and hospitality industries.
Rob earned his Bachelor’s in Business Administration from Merrimack College and is a Certified Public Accountant (inactive).
Dragan joined Vigilant Biosciences in January 2020 as COO to lead product development and global operations including offshore and domestic manufacturing. Dragan brings 30 years of medical device experience working in various management roles. He holds over 60 US and International Patents in the area of medical devices, consumer electronics and medical sensor technologies. Previously, Dragan served as Chief Operating Officer/Chief Technical Officer of Perseon Corporation focusing on interventional radiology cancer treatments. In 2012, he was appointed Chief Technical Officer by Inova Labs where he successfully developed and released to the market ACTIVOX, a portfolio of portable oxygen products. The company was acquired by ResMed in 2016 and he was appointed Vice President of R&D, Oxygen Products. Prior to working at Inova Labs, Dragan served as Vice President of R&D at Thermage, as well as, Vice President of Research and Development/Chief Scientist with Solta Medical. He also held the position of Senior Director of Global Advanced Technologies and IP with Maxwell Technologies. Dragan served as the Executive Director of Engineering and Advanced Technologies with the American Technology Corporation and Molecular Reflections Corporation in biopharma advanced sensors. During his tenure with Procter and Gamble from 1996 until 2000, Dragan spearheaded efforts related to novel new consumer biosensor and portable medical devices applications. Dr. Nebrigic held an adjunct Professor position of Electrical Engineering with the University of Cincinnati.
Dr. Nebrigic earned a Ph.D. in Electrical and Computer Engineering from the University of Cincinnati and a Master of Science in Electrical and Computer Engineering and Technical Physics from the University of Belgrade Serbia.
Ben joined Vigilant Biosciences in January 2020 as Chief Commercial Officer to spearhead the organization’s commercial growth globally. Ben has over 25 years experience in healthcare sales and marketing, focused mainly in the areas of medical device, dental, oncology and diagnostics. His most recent leadership position was in personalized medicine and diagnostics with Myriad Genetic Laboratories. Prior to Myriad, Ben served as President and COO of Perseon Corporation, a leader in ablative technologies in the oncology space. He earlier served as Vice President of Sales, Americas for Solta Medical and Vice President, Sales and Marketing with Lifecore Biomedical, a leader in dental implant technology, where he led all global commercial operations.
Ben earned a Bachelor’s Degree in Business Administration from the University of North Texas.
Michael Donovan Ph.D., M.D. joined Vigilant Biosciences in 2015 and serves as the Chief Medical Officer. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid–based assays and coupled mathematical applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Along with his clinical duties, Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York.
In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. where he served as laboratory director and was responsible for the implementation and execution of several clinical trials.
Dr. Donovan earned a B.S. in Zoology from Rutgers University, a Master of Science in Endocrinology and a Ph.D. in Cell and Developmental Biology with Post–Doctoral studies at Harvard Medical School. He earned his M.D. from the University of Medicine and Dentistry of New Jersey.
Elizabeth Franzmann, M.D. is Vigilant Biosciences’ Scientific Founder and serves as the Chief Scientific Officer since 2014. Her innovative clinical research on selective salivary biomarkers for head and neck squamous cell carcinoma serves as the foundation for Vigilant Biosciences’ product line. Dr. Franzmann is certified by the American Board of Otolaryngology and a Fellow of the American College of Surgeons. She is a Professor of Otolaryngology at the University of Miami, Miller School of Medicine specializing in head and neck surgery. She has been recognized as one of the “Best Doctors in America”. Over the past decade, she has worked in close partnership with Vigilant Biosciences, translating bench research into solutions that address unmet patient needs. Her work has been funded by foundations, state and federal agencies with numerous resulting patents and publications in well-respected, and peer-reviewed journals.
Dr. Franzmann earned a Bachelor of Science and Doctorate of Medicine at the University of California, Los Angeles.
Kris joined Vigilant Biosciences in September 2018 and serves as Vice President, Regulatory, Quality & Clinical to support the Company’s commercial expansion, including its entry into the US market. Kris has over 25 years of experience in global regulatory management of complex medical device and combination products. She has held officer–level positions for entrepreneurial and established organizations, including Mentor Corporation (J&J) and Solta Medical (Bausch Health) where she led the company’s global regulatory, quality and clinical functions. Additionally, she has worked at several other leading medical device and pharmaceutical companies, successfully attaining international regulatory approvals, conducting complex clinical trials, and achieving quality objectives.
Kris holds a Bachelor of Arts in Literature from Northwestern University and certification from the Regulatory Affairs Professionals Society (RAPS).